相关实验视频
Updated: Jan 10, 2026

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.0K
在早期帕金森病的初始治疗中构建个性化治疗规则
Zachary P Brehm1, Ruth B Schneider2,3, Charles S Venuto2,3
1Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
Pharmacotherapy
|November 28, 2025
概括
一种新的机器学习方法创造了个性化的帕金森病治疗规则,平衡了运动功能的改善和减少并发症风险. 这种方法优化了对个体患者的治疗选择.
科学领域:
- 神经学 神经学
- 机器学习 机器学习
- 个性化医疗是个性化的医疗.
背景情况:
- 多巴胺类疗法如利沃多巴和多巴胺受体激动剂 (DRA) 是帕金森病 (PD) 运动症状的标准.
- 这些治疗可以导致运动并发症,包括动力障碍和磨损发作.
研究的目的:
- 为帕金森病的第一线治疗制定个性化的治疗规则.
- 该规则旨在最大限度地提高运动功能的改善,同时在两年内将并发症风险保持在患者和临床医生同意的门以下.
主要方法:
- 在 CALM-PD 和 STEADY-PD III 试验中的统一数据上使用了机器学习技术.
- 根据特定的风险值生成了一个决定规则,用于根据特定的风险值将患者分配给勒沃多巴或DRA.
- 通过将其结果与将所有患者分配到单一治疗的政策进行比较来评估该规则.
主要成果:
- 相比于普遍的DRA分配,最佳决策规则改善了平均运动分数 (MDS-UPDRS第3部分).
- 它还产生了较低的运动并发症的平均概率,而不是普遍的利沃多巴分配.
- 为了规则的开发和验证,需要进一步的数据.
结论:
- 一个最佳的决策规则可以提高帕金森病的数据驱动治疗决策.
- 这种方法有效地平衡了基于个人可接受的风险水平的治疗益处和风险.
相关概念视频
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Dosage Regimen: Individualization
154
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
154

